Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
You are in: eMedicine Specialties > Pediatrics > Rheumatology

Takayasu Arteritis

Last Updated: March 27, 2006
Email to a Colleague
Synonyms and related keywords: TA, Takayasu's arteritis, Takayasu disease, Takayasu's disease, Takayasu syndrome, Takayasu's syndrome, pulseless disease, nonspecific aortoarteritis, reverse coarctation, aortic arch syndrome, aortitis syndrome

  AUTHOR INFORMATION Section 1 of 11    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Author: Christine Hom, MD, Assistant Professor, Department of Pediatrics, Division of Pediatric Rheumatology, New York Medical College

Christine Hom, MD, is a member of the following medical societies: American College of Rheumatology, American Medical Association, and Arthritis Foundation

Editor(s): Barry L Myones, MD, Director of Research, Pediatric Rheumatology Center, Texas Children's Hospital at Houston; Associate Professor, Departments of Pediatrics & Immunology, Pediatric Rheumatology Section, Baylor College of Medicine; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Thomas JA Lehman, MD, Clinical Professor of Pediatrics, Weill-Cornell University; Chief, Department of Pediatrics, Division of Pediatric Rheumatology, Hospital for Special Surgery; Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine; and Norman T Ilowite, MD, Professor of Pediatrics, Albert Einstein College of Medicine; Chief, Department of Pediatrics, Division of Rheumatology, Schneider Children's Hospital

Disclosure


  INTRODUCTION Section 2 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Background: In 1908, Mikito Takayasu, a Japanese ophthalmologist, reported the association of retinal arteriovenous anastomoses and absent upper extremity pulses. Takayasu arteritis (TA) is a chronic inflammatory disease of the aorta and its major branches. TA is a large vessel vasculitis of unknown origin that most often affects young women in the second and third decades of life. TA has been reported in children as young as 6 months and in adults of every age.

The initial complaints may be nonspecific constitutional signs and symptoms (eg, fever, weight loss, lethargy). Because these complaints lack specificity, the correct diagnosis may be delayed for months or years. On histologic examination, the aorta demonstrates evidence of inflammation. Mixed areas of stenosis or aneurysm formation are found on angiogram or magnetic resonance angiography (MRA). Vascular insufficiency related to stenosis and thrombosis of affected vessels may cause renovascular hypertension, neurologic symptoms, or lower extremity claudications.

Cardiac involvement may include aortic regurgitation and congestive heart failure resulting from myocarditis or increased afterload. Often the diagnosis of TA is made when a widened mediastinum is appreciated on chest roentgenogram and a tumor is suspected. CT scan instead demonstrates a widened aortic arch.

Despite the term pulseless disease, which is a synonym for TA, the predominant finding in individuals with TA is asymmetric pulse. Absent peripheral pulses occur late in the course of the disease. While 5-year survival rates exceed 90%, the disease has a high incidence of residual morbidity.

Pathophysiology: TA is characterized by granulomatous inflammation of the aorta and its major branches, leading to stenosis, thrombosis, and aneurysm formation. The lesions of TA are segmental with a patchy distribution.

Mononuclear infiltration of the adventitia occurs early in the course of the disease, with cuffing of the vasa vasorum. Granulomatous changes may be observed in the tunica media with Langerhans cells and central necrosis of elastic fibers and smooth muscle cells. A panarteritis with infiltrates of lymphocytes, plasma cells, histiocytes, and giant cells is present. Later, fibrosis of the media and acellular thickening of the intima compromise the vessel lumen. Wrinkling of the intima is visible on gross examination.

Stenoses are found in 90% of patients with TA disease. Often patients have poststenotic dilatations and other aneurysmal areas. Stenotic arterial segments result in varied ischemic symptoms. These symptoms may range from abdominal pain after eating secondary to narrowing of the mesenteric arteries to renovascular hypertension to claudication of extremities. Endothelial activation leads to a hypercoagulable state predisposing the patient to thrombosis. Congestive heart failure in individuals with TA may occur as a result of hypertension, aortic root dilation, or myocarditis. Transient ischemic attacks, cerebrovascular accidents, mesenteric ischemia, carotidynia, and claudication may occur. Symptoms of vascular compromise may be minimized by the development of collateral circulation with the slow onset of stenosis. Vessel wall dissection or aneurysm may occur in areas weakened by inflammation.

One hypothesis for granulomatous vasculitis development is that antigens deposited in vascular walls activate CD4+ T cells, followed by release of cytokines chemotactic for monocytes. These monocytes are transformed into macrophages that mediate endothelial damage and granuloma formation in the vessel wall. A mouse model supports this hypothesis. When syngeneic T cells sensitized to vascular smooth muscle cells were injected into mice, a granulomatous vasculitis of the pulmonary arterioles occurred in 20% of the mice. Human studies suggesting endothelial cell activation have demonstrated increased expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with TA. Humoral immunity also is believed to be involved in this disease; antiaorta antibodies and antiendothelial cell antibodies have been found in patients with TA. Immunoglobulin G, immunoglobulin M, and properdin are found in lesions from pathologic specimens.

Frequency:

  • In the US: In Minnesota's Olmstead County, incidence of TA was estimated at 2.6 per million. However, the applicability of this number to the diverse population of the US as a whole is uncertain.
  • Internationally: TA is a common affliction in third world countries, where the disease is associated closely with tuberculosis. The nature of this association is unclear because most patients with TA in the US do not have tuberculosis. In contrast, many third world physicians assume tuberculosis in every patient with TA.

Mortality/Morbidity:

  • Because the disease is rare in the US, accurate survival data are uncertain. One study has quoted a survival rate of 85-95% at 15 years. In a 1994 study, only 2% of deaths were attributed directly to TA. Japanese studies also support 90-95% survival rates.
  • In contrast, in a 1991 series involving 26 Mexican children aged 3-15 years, the 5-year survival rate was only 35%. Deaths resulted from rupture of aorta or aneurysms (2), stroke (2), cardiac failure (2), and peritonitis and ventricular fibrillation.
  • Morbidities in persons with TA are related to ischemia and hypertension and include congestive heart failure, transient ischemic attacks, stroke, and visual disturbances. Chronic low-grade dissection of the aorta may cause recurrent chest pain for years. At autopsy, children with TA who have died from acute rupture of the aorta often are found to have evidence of multiple prior small dissections that did not progress.

Race: TA more frequently is found in Asian populations but has been described in patients of all races.

  • Japanese patients with TA have a higher incidence of aortic arch involvement. In contrast, series from India report higher incidences of thoracic and abdominal involvement.
  • In US patients with TA, the most commonly involved vessels are the left subclavian, superior mesenteric, and abdominal aorta. In US children with TA, lesions of the thoracic and abdominal aorta, rather than lesions of the aortic arch, are found most commonly. However, all patterns of vascular involvement have been observed in every country.

Sex:

  • Females comprise 80-90% of patients with TA.
  • Pediatric studies are more varied. Sex distribution usually mirrors the 80-90% female preponderance observed in adults. Series of studies of TA in childhood from India and South Africa report a 2:1 female-to-male ratio. However, these are countries in which TA is associated strongly with tuberculosis, and additional etiologic and pathophysiologic factors may be present.

Age:

  • TA is the most common large vessel vasculitis of adolescence.
  • TA is an uncommon vasculitis in children. The most common are postinfectious vasculitides, Henoch-Schönlein purpura, polyarteritis nodosa, and Kawasaki disease.
  • Most cases of TA present in persons aged 10-30 years. In a series of patients with TA, 20-35% were younger than 20 years at diagnosis. The youngest patient reported was aged 6 months.


  CLINICAL Section 3 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

History:

  • Systemic symptoms include the following:
    • Fever, night sweats
    • Fatigue
    • Weight loss
    • Myalgia and/or arthralgia and/or arthritis
    • Skin rash (eg, erythema nodosum, pyoderma gangrenosum)
    • Headaches and/or dizziness and/or syncope
    • Congestive heart failure, palpitations, angina
    • Hypertension (may be paroxysmal)
  • Symptoms related to ischemia include the following:
    • Ischemic stroke and/or transient ischemic attack
    • Visual disturbances (eg, blurred vision, diplopia, amaurosis)
    • Carotidynia
    • Abdominal pain
    • Claudications (vary due to the development of collateral circulations; symptom is rare in children)

Physical:

  • Blood pressure difference greater than 30 mm Hg between arms
  • Asymmetric pulses
  • Diminished or absent pulses (midaortic lesions found in children may not affect pulses)
  • Asymmetric pulses (common) and absent pulses (rare), even in the later stages of the disease (awareness of this is critical)
  • Poststenotic dilatations producing what appear to be bounding pulses (often present)
  • Hypertension (may be paroxysmal): Since this typically results from renovascular compromise, this is a high-renin hypertension.
  • Bruits, especially over subclavian arteries or aorta
  • Funduscopic examination
    • Retinal hemorrhages
    • Cotton-wool exudates
    • Venous dilatation and beading
    • Microaneurysms of peripheral retina
    • Optic atrophy
    • Vitreous hemorrhage
    • Classic wreathlike peripapillary arteriovenous anastomoses (extremely rare)
  • Reported skin lesions including erythema nodosum-like lesions, pyoderma gangrenosum, leukocytoclastic vasculitis, and panniculitis

Causes:

  • TA has been reported in identical twins, leading to hypotheses of a hereditary basis for disease. In Japan and Korea, TA is associated with human leukocyte antigens HLA-A10, B5, Bw52, DR2, and DR4. These associations have not been confirmed in Western studies. TA is associated with HLA-B22 in the US.
  • Although early reports associated tuberculosis with TA, these involved populations endemic for tuberculosis, and population studies have not borne out this association. Others report increased incidence of positive purified protein derivative relative to control patients. The true nature of the association with tuberculosis (if any) is unclear. Patients with TA do not improve with antituberculous treatment.
  DIFFERENTIALS Section 4 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Acute Lymphoblastic Leukemia
Behcet Syndrome
Fever Without a Focus
Hodgkin Disease
Polyarteritis Nodosa
Rheumatic Fever


Other Problems to be Considered:

Systemic-onset juvenile rheumatoid arthritis
Migraine
Infection
Malignancy
Cogan syndrome

Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Pictures
Bibliography

Click for related images.

Related Articles
Acute Lymphoblastic Leukemia

Behcet Syndrome

Fever Without a Focus

Hodgkin Disease

Polyarteritis Nodosa

Rheumatic Fever


Patient Education
Click here for patient education.



  WORKUP Section 5 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Lab Studies:

  • TA has no specific markers.
  • Complete blood count reveals a normochromic normocytic anemia in 50% of patients with TA. Acute phase reactants are elevated, with leukocytosis and thrombocytosis.
  • Westergren erythrocyte sedimentation rate is elevated.
  • Comprehensive metabolic profile may indicate elevated transaminases and hypoalbuminemia.
  • The von Willebrand factor–related antigen (factor VIII–related antigen) may be elevated.
  • Antiendothelial antibodies are present.
  • Antinuclear antibody usually is negative.
  • Rheumatoid factor is elevated in 15% of individuals with TA.
  • Increased levels of immunoglobulins G, M, and A are present.

Imaging Studies:

  • Arteriography either by invasive angiography or by MRA
    • Arteriography is the criterion standard for assisting in making the diagnosis of TA. However, the use of MRA is increasing rapidly.
    • Peripheral blood pressure monitoring frequently is inaccurate in persons with TA; pressure readings during angiography alone may reveal aortic root hypertension.
    • Drawbacks to arteriography, including morbidity from use of contrast dye in patients with renal disease and cumulative radiation exposure over time, can be avoided by using MRA.
    • Arteriography often demonstrates long, smooth, tapered narrowings or occlusions. Stenoses occur in 90-100% of patients with TA and aneurysm formation in only 27%. Three-dimensional MRA imaging of the aorta and its branches are providing exciting new data that may improve the understanding of the disease.
    • Some authors recommend arteriography of the entire aorta.
  • Magnetic resonance imaging, magnetic resonance angiography, computed tomography
    • These examinations are useful for serial examinations and diagnosis in the early phase of TA.
    • CT scan and MRI may demonstrate mural thickening of the aorta and luminal narrowing.
    • Use of contrast may reveal inflammatory lesions prior to the development of stenoses; these lesions may be missed by angiography.
    • Aortic lesions including stenosis, dilatation, wall thickening, and mural thrombi are well visualized on MRI, which is less adequate in visualizing distal lesions of the subclavian vessels and common carotids.
    • Noncontrast T2-weighted STIR images may be used to monitor edema in the aortic wall, which may be a surrogate for inflammation; edema was found in 94% of patients with clinically active disease.
    • Edema was found in 56% of patients in clinical remission, similar to the 42-44% of patients found to have active vasculitis on pathology from bypass specimens from patients who were in clinical remission. The prognostic significance of vessel edema is uncertain, as progression of lesions occurs in areas without edema, and progression may be absent from areas with edema on subsequent studies.
  • Gallium-67 radionuclide scan: This scan may demonstrate increased uptake in the aorta and branches.
  • High-resolution ultrasonography
    • Duplex Doppler may be used to evaluate and monitor disease in the common carotids and subclavian arteries; however, this imaging study is not useful in evaluating the aorta.
    • Carotid evaluation reveals a homogenous circumferential thickening of the vessel wall that is distinguishable from atherosclerotic thickening.
  • Chest radiography: Chest radiographs may reveal widening of the ascending aorta, irregular descending aorta, aortic calcifications, and rib notching (late findings).

Other Tests:

  • Echocardiography
    • Perform echocardiography at baseline to evaluate the aortic valve.
    • Perform follow-up echocardiography as indicated to monitor aortic insufficiency.
Histologic Findings: Mononuclear infiltration of the adventitia with perivascular cuffing of the vasa vasorum occurs early in the disease. Granulomatous changes may be observed in the tunica media with Langerhans cells and central necrosis of elastic fibers and smooth muscle cells. Later, fibrosis of the media and acellular thickening of the intima may compromise the vessel lumen. Grossly, wrinkling of the intima is found.

Histologic specimens seldom are available due to the large vessels affected, with the exceptions of specimens obtained during autopsy and bypass surgery.

  TREATMENT Section 6 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Medical Care: Medical evaluation and treatment can be performed on an outpatient basis unless the patient is acutely ill. Goals of medical therapy are to control active inflammation and to normalize clinical and laboratory parameters while preventing further vascular damage.

Surgical Care: Following the acute phase, patients with fibrotic changes require surgical treatment of symptomatic stenotic or occlusive disease. This can be achieved by percutaneous angioplasty or stenting or, in severe cases, by resection and placement of a manmade graft. Children with TA rarely require bypass surgery of carotid stenting.

  • Percutaneous balloon angioplasty of the aorta
    • Percutaneous balloon angioplasty of the aorta is reported to normalize systolic and diastolic blood pressures within 24 hours, with improvement of exercise tolerance and restoration of peripheral pulses.
    • Both renovascular hypertension and congestive failure due to increased afterload are improved.
    • Improvement has been sustained for as long as 3-5 years.
  • Endovascular stenting
    • Endovascular stenting is used in patients with severe stenoses, hypertension, or ischemia during the fibrotic phase of the disease.
    • Multiple stents have been used in children to relieve long-segment renal artery stenosis and attendant renovascular hypertension.
    • Children with TA who have received stents have lowered arterial blood pressures and decreased requirement for antihypertensives.
    • Immunosuppressant-eluting stents could potentially deliver local treatment at sites of inflammation.

Consultations:

  • Pediatric rheumatology
  • Ophthalmology
  • Pediatric cardiology
  • Vascular surgery
  • Interventional radiology

Activity: Patient activity is generally self-limiting, based on cardiac status.
  MEDICATION Section 7 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

The mainstay of initial therapy is daily high-dose corticosteroid administration. Maintain high-dose treatment for several weeks until all evidence of active disease has resolved. Among patients receiving this treatment, 60% respond; however, 40% relapse on steroid taper.
Patients who do not respond to corticosteroids or who relapse during corticosteroid taper require a second agent. Regimens including weekly methotrexate and daily cyclophosphamide have been used in individuals with glucocorticoid-resistant TA. Low-dose weekly methotrexate also has been used as a steroid-sparing agent for patients not tolerating corticosteroid taper. Cyclosporine may be an alternative therapy offering lower ovarian toxicity than cyclophosphamide. Recent reports indicate mycophenolate mofetil may help treat glucocorticoid-resistant disease. Leflunomide has been used in glucocorticoid- and methotrexate-resistant disease. TNF inhibition with etanercept or infliximab has also been used in relapsing disease or glucocorticoid-dependent disease.

Drug Category: Immunosuppressive agents -- Used to suppress inflammation, thus delaying progression of thrombosis, stenosis, and aneurysm.
Drug Name
Prednisone (Deltasone, Meticorten, Orasone, Sterapred) -- Immunosuppressant for treatment of autoimmune disorders; may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. Stabilizes lysosomal membranes and also suppresses lymphocytes and antibody production.
Adult Dose1-2 mg/kg/d PO qd or divided bid
Pediatric DoseNot to exceed 1-2 mg/kg/d PO qd or divided bid
ContraindicationsDocumented hypersensitivity; serious infections; systemic fungal infections; varicella; GI bleeding or ulceration
InteractionsInduction of cytochrome P450 enzymes decreases vaccine effectiveness; phenytoin and rifampin decrease corticosteroid effectiveness
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in patients with hypertension, congestive heart failure, or diabetes
Drug Name
Methotrexate (MTX, Rheumatrex, Folex PFS) -- Inhibits tetrahydrofolate reductase and has potent anti-inflammatory effects possibly mediated through adenosine receptors. Unknown mechanism of action in treatment of inflammatory reactions; may affect immune function. Ameliorates symptoms of inflammation (eg, pain, swelling, stiffness). Adjust dose gradually to attain satisfactory response.
Adult Dose10-20 mg/wk PO/IM/SC
Pediatric Dose5-15 mg/m2/wk PO/IM/SC
ContraindicationsDocumented hypersensitivity; hepatic or renal impairment; bone marrow suppression
InteractionsNSAIDs may cause increased or prolonged levels of MTX; MTX may decrease clearance of theophylline; penicillins may decrease renal excretion of MTX; broad-spectrum PO antibiotics may decrease MTX bioavailability; large doses of folate may decrease MTX's efficacy; additional folate antagonists (eg, TMP/SMX) may have additive myelosuppression
Pregnancy X - Contraindicated in pregnancy
PrecautionsPhotosensitivity; bone marrow suppression; hepatotoxicity; pulmonary fibrosis; teratogenicity; oncogenic potential
Drug Name
Cyclophosphamide (Cytoxan, Neosar) -- Alkylating agent, believed to be cytotoxic to dividing cells by cross-linking cellular DNA. Processed in liver to active metabolites; byproducts (eg, acrolein) accumulate in bladder and cause cystitis.
Adult Dose1-2.5 mg/kg/d PO or 500 mg to 1 g/m2 BSA IV every mo
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; severely depressed bone marrow function; with PO dosing, severe hemorrhagic cystitis is 15%, but with IV hydration with MESNA, hemorrhagic cystitis occurs rarely if ever
InteractionsAllopurinol; chloramphenicol; digoxin; hydrochlorothiazide; live vaccines; pentostatin; rotavirus vaccine; succinylcholine; tamoxifen
Pregnancy D - Unsafe in pregnancy
PrecautionsIncreased risk of infections; alopecia; hemorrhagic cystitis; teratogenicity; oncogenic potential; male and female infertility; cardiomyopathies
Drug Name
Cyclosporine (Sandimmune, Neoral) -- Cyclic polypeptide that suppresses some humoral immunity and, to a greater extent, cell-mediated immune reactions such as delayed hypersensitivity, allograft rejection, experimental allergic encephalomyelitis, and graft vs host disease for a variety of organs. Doses used in autoimmune diseases are generally lower than those used in transplant patients. Initiate at lowest dose possible, then taper to lowest effective dose as soon as possible. Attempt discontinuing cyclosporine to determine if therapy can stop.
Adult Dose1-3 mg/kg/d PO initially; may increase gradually to 5 mg/kg/d PO as needed to control symptoms; maintain at lowest effective dose
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; uncontrolled hypertension or malignancies; do not administer concomitantly with PUVA or UVB radiation in psoriasis since it may increase risk of cancer
InteractionsCarbamazepine, phenytoin, isoniazid, rifampin, and phenobarbital may decrease cyclosporine concentrations; azithromycin, itraconazole, nicardipine, ketoconazole, fluconazole, erythromycin, verapamil, grapefruit juice, diltiazem, aminoglycosides, acyclovir, amphotericin B, and clarithromycin may increase cyclosporine toxicity; acute renal failure, rhabdomyolysis, myositis, and myalgias increase when taken concurrently with lovastatin
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsEvaluate renal and liver functions often by measuring BUN, serum creatinine, serum bilirubin and liver enzymes; may increase risk of infection and lymphoma; reserve IV use only for those who cannot take PO
  FOLLOW-UP Section 8 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Further Outpatient Care:

Complications:

Prognosis:

Patient Education:

  MISCELLANEOUS Section 9 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Medical/Legal Pitfalls:

  • Failure to recognize underlying malignancy
  • Failure to recognize signs and symptoms of TA

Special Concerns:

  • Patients with ischemia in all 4 extremities may have falsely low peripheral blood pressures. Accurate blood pressure monitoring in such patients can be obtained reliably only by central systemic measurements.
  • Early diagnosis can be difficult due to nonspecific early symptoms; perform a thorough evaluation to eliminate other diagnoses.
  PICTURES Section 10 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Caption: Picture 1. Aortogram of a 15-year-old adolescent girl with Takayasu arteritis. Note large aneurysms of descending aorta and dilatation of innominate artery.
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: X-RAY
Caption: Picture 2. MRI of thorax of 15-year-old adolescent girl with Takayasu arteritis. Note aneurysms of descending aorta.
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: MRI
Caption: Picture 3. Coronal MRI of abdomen of 15-year-old adolescent girl with Takayasu arteritis. Note thickening and tortuosity of abdominal aorta proximal to kidneys.
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: MRI
  BIBLIOGRAPHY Section 11 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

  • Arend WP, Michel BA, Bloch DA, et al: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990 Aug; 33(8): 1129-34[Medline].
  • Arora P, Kher V, Singhal MK, et al: Renal artery stenosis in aortoarteritis: spectrum of disease in children and adults. Kidney Blood Press Res 1997; 20(5): 285-9[Medline].
  • Baumgartner D, Sailer-Hock M, Baumgartner C: Reduced aortic elastic properties in a child with Takayasu arteritis: case report and literature review. Eur J Pediatr 2005 Nov; 164(11): 685-90[Medline].
  • Daina E, Schieppati A, Remuzzi G: Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999 Mar 2; 130(5): 422-6[Medline].
  • de Leeuw K, Bijl M, Jager PL: Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculitides. Clin Exp Rheumatol 2004; 22(6 Suppl 36): S21-6[Medline].
  • Della Rossa A, Tavoni A, Merlini G: Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. Rheumatology (Oxford) 2005 Aug; 44(8): 1074-5[Medline].
  • Haberhauer G, Kittl EM, Dunky A: Beneficial effects of leflunomide in glucocorticoid- and methotrexate- resistant Takayasu's arteritis. Clin Exp Rheumatol 2001 Jul-Aug; 19(4): 477-8[Medline].
  • Hoffman GS, Leavitt RY, Kerr GS, et al: Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994 Apr; 37(4): 578-82[Medline].
  • Hoffman GS, Merkel PA, Brasington RD: Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004 Jul; 50(7): 2296-304[Medline].
  • Karam EZ, Muci-Mendoza R, Hedges TR 3rd: Retinal findings in Takayasu's arteritis. Acta Ophthalmol Scand 1999 Apr; 77(2): 209-13[Medline].
  • Kern P, Kalden JR, Manger B: Inflammatory arterial stenosis: followup with color Doppler sonography. Arthritis Rheum 2000 Jan; 43(1): 238[Medline].
  • Kerr GS, Hallahan CW, Giordano J, et al: Takayasu arteritis. Ann Intern Med 1994 Jun 1; 120(11): 919-29[Medline].
  • Kerr GS: Takayasu's arteritis. Rheum Dis Clin North Am 1995 Nov; 21(4): 1041-58[Medline].
  • Kissin EY, Merkel PA: Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 2004 Jan; 16(1): 31-7[Medline].
  • Lambert M, Hatron PY, Hachulla E, et al: Takayasu's arteritis diagnosed at the early systemic phase: diagnosis with noninvasive investigation despite normal findings on angiography. J Rheumatol 1998 Feb; 25(2): 376-7[Medline].
  • Liang P, Hoffman GS: Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005 Jan; 17(1): 16-24[Medline].
  • Martini A: Behcet's disease and Takayasu's disease in children. Curr Opin Rheumatol 1995 Sep; 7(5): 449-54[Medline].
  • Miller JH, Gunarta H, Stanley P: Gallium scintigraphic demonstration of arteritis in Takayasu disease. Clin Nucl Med 1996 Nov; 21(11): 882-3[Medline].
  • Morales E, Pineda C, Martinez-Lavin M: Takayasu's arteritis in children. J Rheumatol 1991 Jul; 18(7): 1081-4[Medline].
  • Mwipatayi BP, Jeffery PC, Beningfield SJ: Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 2005 Mar; 75(3): 110-7[Medline].
  • Perniciaro CV, Winkelmann RK, Hunder GG: Cutaneous manifestations of Takayasu's arteritis. A clinicopathologic correlation. J Am Acad Dermatol 1987 Dec; 17(6): 998-1005[Medline].
  • Schmidt WA, Blockmans D: Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005 Jan; 17(1): 9-15[Medline].
  • Shetty AK, Stopa AR, Gedalia A: Low-dose methotrexate as a steroid-sparing agent in a child with Takayasu's arteritis. Clin Exp Rheumatol 1998 May-Jun; 16(3): 335-6[Medline].
  • Sun Y, Yip PK, Jeng JS, et al: Ultrasonographic study and long-term follow-up of Takayasu's arteritis. Stroke 1996 Dec; 27(12): 2178-82[Medline].
  • Tyagi S, Kaul UA, Nair M, et al: Balloon angioplasty of the aorta in Takayasu's arteritis: initial and long-term results. Am Heart J 1992 Oct; 124(4): 876-82[Medline].
  • Tyagi S, Sharma VP, Arora R: Stenting of the aorta for recurrent, long stenosis due to Takayasu's arteritis in a child. Pediatr Cardiol 1999 May-Jun; 20(3): 215-7[Medline].
  • Uthman IW, Bizri AR, Hajj Ali RA, et al: Takayasu's arteritis presenting as fever of unknown origin: report of two cases and literature review. Semin Arthritis Rheum 1999 Feb; 28(4): 280-5[Medline].
  • Yamada I, Numano F, Suzuki S: Takayasu arteritis: evaluation with MR imaging. Radiology 1993 Jul; 188(1): 89-94[Medline].

Takayasu Arteritis excerpt